Trials / Completed
CompletedNCT01249027
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,605 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: * Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use * Evaluate patient compliance to dual antiplatelet therapy (DAPT)
Conditions
- Angioplasty
- Chronic Coronary Occlusion
- Stent Thrombosis
- Vascular Disease
- Myocardial Ischemia
- Coronary Artery Stenosis
- Coronary Disease
- Coronary Artery Disease
- Coronary Restenosis
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) | Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study. |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2016-12-01
- Completion
- 2017-01-01
- First posted
- 2010-11-29
- Last updated
- 2019-03-01
- Results posted
- 2019-03-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01249027. Inclusion in this directory is not an endorsement.